Last month, business news outlets were reporting that stock prices for pharmaceutical firms Pfizer and Merck took a tumble after financial analysts downgraded the performance of both firms over concerns about impending patent cliffs or exclusivity issues – although more recent reports paint a mostly promising picture for the companies, thanks to upcoming acquisitions. A pharmaceutical analyst for UBS downgraded Pfizer from buy to neutral, citing the loss of patent protection in the 2025 to 2029 timeframe for several drugs which contributed 30 percent of Pfizer’s total revenue in 2015. For Merck, although patent expiry wasn’t cited in a note from a pharmaceutical analyst from BMO, that analyst dropped Merck’s rating from outperform to market perform based on the expectation that the company’s blockbuster cancer drug Keytruda would face increased competition in the immuno-oncology field during 2019. As of January 30, stock prices for both firms were down by at least a dollar per share from their closing price on January 23. The downgrades for both firms are further proof of the importance of maintaining exclusivity through patent protection to pharmaceutical firms.
The post Merck and Pfizer Downgrades on Patent Cliff Concerns Signal Importance of Patents to Pharma appeared first on IPWatchdog.com | Patents & Patent Law.
Merck and Pfizer Downgrades on Patent Cliff Concerns Signal Importance of Patents to Pharma
No Comments
Business
- How Patents Enable Mavericks and Challenge Incumbents
- Innovation Alliance Urges Biden Administration to Support Patent Rights
- Trade and Commerce in West Africa and How it Influences IP Rights
- Supreme Court Ponders Proper Application of the Computer Fraud and Abuse Act
- How Patents Helped Sprout the World’s First Plantable Pencil
Recent Posts
- USPTO Responds to Patent Bar Gender Gap Inquiry, Mulls Changes to Registration Process
- How Patents Enable Mavericks and Challenge Incumbents
- ipAwarenessAssessment: Inventors and Business Owners Should Start Their IP Journey with this USPTO-NIST Tool
- Other Barks & Bites for Friday, January 22: Iancu and Peter Step Down from USPTO, CJEU Asked Whether Preliminary Injunction Standard Burdens Patent Owners, SCOTUS Denial Leaves Invalidation of Idenix Genus Patent Claims Untouched
- US Inventor Backs SCOTUS Petition to Clarify Claim Construction Principles